 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
10-12-2011
Insider Buy |
Partners L. P/IL Bvf
>10% Owner |
$5.96
CAGR »
|
$175,672.50
29,500 shares |
10-11-2011
Insider Buy |
Partners L. P/IL Bvf
>10% Owner |
$5.60
CAGR »
|
$413,480.09
73,900 shares |
Also See: Institutional Holders of NBIX
Also See: SEC filings
Below we present the annualized performance delivered by Neurocrine Biosciences stock since 10-12-2011 (the date of the most recent
insider purchase). The performance of the investment from the time Neurocrine Biosciences insider buying occurred is the ultimate
test of whether insiders were right about NBIX being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/13/2011 |
|
| End date: |
05/02/2024 |
|
| Start price/share: |
$6.42 |
|
| End price/share: |
$139.83 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
2,078.04% |
|
| Average Annual Total Return: |
27.80% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$217,872.61 |
|
| Years: |
12.56 |
|
Neurocrine Biosciences Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Neurocrine Biosciences insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding NBIX
|
|
Free NBIX Email Alerts:
